



**MBX-2982** 

**Catalog No: tcsc0745** 

Available Sizes		
Size: 5mg		
Size: 10mg		
Size: 50mg		
Specifications		
CAS No: 1037792-44-1		
Formula: C <sub>22</sub> H <sub>24</sub> N <sub>8</sub> OS		
Pathway: GPCR/G Protein		
Target: GPR119		
Purity / Grade: >98%		
<b>Solubility:</b> 10 mM in DMSO		
Observed Molecular Weight:		

## **Product Description**

448.54

MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119





) agonist.

IC50 & Target: GPR119<sup>[1]</sup>

In Vitro: In cells pre-treated with MBX-2982 (1  $\mu$ M) in "chronic incubation/washout" experiments, cAMP accumulation captured by IBMX inclusion is significantly increased compared to control cells (P50s of 8.67±0.11 and 8.93±0.17, respectively. Likewise, a large but less severe shift in concentration responses (57.54 fold) is observed for MBX-2982 with respective sustained and acute pEC<sub>50</sub>s of 7.03±0.13 and 8.79±0.12<sup>[1]</sup>.

In Vivo: To examine whether the observations in GLUTag and the primary intestinal cells has physiological relevance, C57BL/6 mice are treated with the GPR119 agonist MBX-2982 at a dose of 10 mg/kg. Note that in order to examine a direct GPR119 effect, no DPP-IV inhibitor is co-administered in this experiment, but a DPP-IV inhibitor is used to preserve active GLP-1 in the blood samples. The plasma GLP-1 levels from the mice dosed with MBX-2982 are increased without a glucose load, indicating that GPR119-mediated GLP-1 secretion is not dependent on glucose<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!